Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression

Zhang, Chunye; Liu, Shuai; Yang, Ming

doi:10.4251/wjgo.v14.i8.1456

Cited by 11 publications

(7 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, it has been demonstrated that patients with COVID-19 develop dysbiotic microbiota, potentially heightening the risk for severe COVID-19 and colorectal cancer [117]. In pancreatic cancer (PC), the alteration of gut microbiota caused by COVID-19 infection showed an impact on PC progression via immune regulation [118]. Recently, it was demonstrated that patients with cancer and COVID-19 have a higher chance of severe symptoms, suggesting an association between the naso-oropharyngeal microbiome, breast cancer, and COVID-19 severity [119].…”

Section: Covid-19 and Lung Cancermentioning

confidence: 99%

The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression

Souza,

Forder,

Pewarchuk

et al. 2023

Cells

View full text Add to dashboard Cite

In recent years, there has been a growing interest in the relationship between microorganisms in the surrounding environment and cancer cells. While the tumor microenvironment predominantly comprises cancer cells, stromal cells, and immune cells, emerging research highlights the significant contributions of microbial cells to tumor development and progression. Although the impact of the gut microbiome on treatment response in lung cancer is well established, recent investigations indicate complex roles of lung microbiota in lung cancer. This article focuses on recent findings on the human lung microbiome and its impacts in cancer development and progression. We delve into the characteristics of the lung microbiome and its influence on lung cancer development. Additionally, we explore the characteristics of the intratumoral microbiome, the metabolic interactions between lung tumor cells, and how microorganism-produced metabolites can contribute to cancer progression. Furthermore, we provide a comprehensive review of the current literature on the lung microbiome and its implications for the metastatic potential of tumor cells. Additionally, this review discusses the potential for therapeutic modulation of the microbiome to establish lung cancer prevention strategies and optimize lung cancer treatment.

show abstract

Section: Covid-19 and Lung Cancermentioning

confidence: 99%

The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression

Souza,

Forder,

Pewarchuk

et al. 2023

Cells

View full text Add to dashboard Cite

show abstract

“…Gut microbiota plays an important role in many metabolic disorders [ 15 , 124 , 125 ], including obesity. Mechanistic studies show that gut microbiota can impact diet metabolism and energy balance, gut permeability, intestinal hormone secretion, insulin resistance, and systemic inflammation [ 126 , 127 ].…”

Section: Clinical Management Of Obesitymentioning

confidence: 99%

The Related Metabolic Diseases and Treatments of Obesity

2022

Self Cite

View full text Add to dashboard Cite

Obesity is a chronic disease characterized by the abnormal or excessive accumulation of body fat, affecting more than 1 billion people worldwide. Obesity is commonly associated with other metabolic disorders, such as type 2 diabetes, non-alcoholic fatty liver disease, cardiovascular diseases, chronic kidney disease, and cancers. Factors such as a sedentary lifestyle, overnutrition, socioeconomic status, and other environmental and genetic conditions can cause obesity. Many molecules and signaling pathways are involved in the pathogenesis of obesity, such as nuclear factor (NF)-κB, Toll-like receptors (TLRs), adhesion molecules, G protein-coupled receptors (GPCRs), programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and sirtuin 1 (SIRT1). Commonly used strategies of obesity management and treatment include exercise and dietary change or restriction for the early stage of obesity, bariatric surgery for server obesity, and Food and Drug Administration (FDA)-approved medicines such as semaglutide and liraglutide that can be used as monotherapy or as a synergistic treatment. In addition, psychological management, especially for patients with obesity and distress, is a good option. Gut microbiota plays an important role in obesity and its comorbidities, and gut microbial reprogramming by fecal microbiota transplantation (FMT), probiotics, prebiotics, or synbiotics shows promising potential in obesity and metabolic syndrome. Many clinical trials are ongoing to evaluate the therapeutic effects of different treatments. Currently, prevention and early treatment of obesity are the best options to prevent its progression to many comorbidities.

show abstract

“…Most of the microbes reside (> 95%) within the gut and maintain intestinal homeostasis[ 53 ]. Dysbiosis of gut microbiota can regulate inflammation and immune response in the TME to promote cancer progression[ 54 , 55 ], including PC[ 56 , 57 ]. A preclinical study showed that gut microbiota can promote PDAC progression by regulating the infiltration and anti-cancer activity of natural killer cells in the TME[ 58 ].…”

Section: Pathogenesis Of Pancreatic Cancer and Relative Molecular Mec...mentioning

confidence: 99%

Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options

Zhang¹,

Liu²,

Yang³

2022

World J Gastroenterol

Self Cite

View full text Add to dashboard Cite

Pancreatic cancer (PC) is the third-leading cause of cancer deaths. The overall 5-year survival rate of PC is 9%, and this rate for metastatic PC is below 3%. However, the PC-induced death cases will increase about 2-fold by 2060. Many factors such as genetic and environmental factors and metabolic diseases can drive PC development and progression. The most common type of PC in the clinic is pancreatic ductal adenocarcinoma, comprising approximately 90% of PC cases. Multiple pathogenic processes including but not limited to inflammation, fibrosis, angiogenesis, epithelial-mesenchymal transition, and proliferation of cancer stem cells are involved in the initiation and progression of PC. Early diagnosis is essential for curable therapy, for which a combined panel of serum markers is very helpful. Although some mono or combined therapies have been approved by the United States Food and Drug Administration for PC treatment, current therapies have not shown promising outcomes. Fortunately, the development of novel immunotherapies, such as oncolytic viruses-mediated treatments and chimeric antigen receptor-T cells, combined with therapies such as neoadjuvant therapy plus surgery, and advanced delivery systems of immunotherapy will improve therapeutic outcomes and combat drug resistance in PC patients. Herein, the pathogenesis, molecular signaling pathways, diagnostic markers, prognosis, and potential treatments in completed, ongoing, and recruiting clinical trials for PC were reviewed.

show abstract

Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression

Cited by 11 publications

References 94 publications

The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression

The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression

The Related Metabolic Diseases and Treatments of Obesity

Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options

Contact Info

Product

Resources

About